Genmab A/S is a Danish biotech company, founded in February 1999 by Florian Schönharting. Genmab is headquartered in Copenhagen. Internationally, Genmab operates through the subsidiaries Genmab BV in Utrecht, the Netherlands, and Genmab, Inc. in Princeton, New Jersey, USA. Genmab is traded on NASDAQ OMX Copenhagen A/S.
The company develops fully human, monoclonal antibodies against cancer, arthritis and several other life-threatening and debilitating diseases with a special technique based on transgenic mice.
Genmab has two approved antibodies, Arzerra® (ofatumumab) to combat certain chronic lymphocytic leukemia indications, and DARZALEX™ (daratumumab) to combat refractory multiple myeloma. Daratumumab is in clinical development with the aim of using it against additional versions of multiple myeloma and for non-Hodgkin's lymphoma. In addition, they have a broad clinical and pre-clinical portfolio of products.
The company’s milestones:
1999: Genmab was founded in Copenhagen, Denmark.
2001: Genmab entered its first major partnership, an antibody development collaboration with Roche.
2004: Genmab received the James D. Watson Helix Award for Outstanding Performance by an International Biotechnology Company.
2009: Arzerra (ofatumumab) reached the US market in 2009 for refractory chronic lymphocytic leukemia.
2010: The DuoBody® bispecific antibody technology platform was introduced.
2012: Genmab entered worldwide agreement with Janssen Biotech, Inc. for daratumumab, a human CD38 monoclonal antibody, for multiple myeloma.
2013: Genmab won Biotech Company of the Year at the Annual Scrip Awards.
2015: DARZALEX ® was approved by the U.S. FDA for patients with multiple myeloma who received at least three prior lines of therapy.
2018: Genmab entered strategic partnership with Immatics Biotechnologies GmbH to discover and develop next-generation bispecific cancer immunotherapies.
2020: Genmab announced very favorable topline results from phase 2 clinical trial of tisotumab vedotin in recurrent or metastatic cervical cancer.
2021: Tivdak® (Tisotumab Vedotin-tftv), a first-in-class antibody-drug conjugate approved in the U.S. for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.
2022: U.S. FDA granted orphan-drug designation to epcoritamab for the treatment of follicular lymphoma.
According to Wikipedia & genmab.com